Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion

Australia's Telix Pharmaceuticals agreed to acquire Germany-based ITM Isotope Technologies Munich SE for approximately $1.65 billion on a cash- and debt-free basis. The transaction is a major healthcare and biotech sector acquisition likely to materially expand Telix's radiopharmaceutical capabilities and could drive significant movement in Telix shares.